CA-LATTICEFLOW-AI
23.4.2024 09:01:32 CEST | Business Wire | Press release
LatticeFlow AI, the leading platform empowering Artificial Intelligence (AI) teams to build performant, safe, and trustworthy AI solutions, proudly announces that it has joined the U.S. AI Safety Institute Consortium (AISIC). LatticeFlow AI researchers will support Working Group #3, focusing on capability evaluations. Together with the National Institute of Standards & Technology (NIST) and other consortium members, LatticeFlow AI will support the development of methods, benchmarks, and testing environments that help organizations operationalize the practices outlined in NIST’s AI Risk Management Framework (RMF).
Dave Henry, SVP of Business Development at LatticeFlow AI, added: “AI safety programs are interdisciplinary in nature, requiring a broad range of management and technical skills to execute. The Consortium brings diverse experts together to create durable and innovative practices that promote trustworthy AI. We look forward to contributing our knowledge of AI model safety and collaborating on new approaches for scalable evaluations.”
Executive Demand for Trustworthy AI
Despite the impressive accuracy of AI models demonstrated in pilots and proof-of-concept projects, building AI solutions that perform reliably on real-world data remains an immense challenge. This affects both technical teams building and delivering AI solutions as well as management teams that need to quantify risks and approve AI solutions for use in business-critical operations. As a result, 85% of the models never make it into production, and out of those that do, 91% degrade over time.
“Unfortunately, high-value AI deployments are being delayed due to developer delay, insufficient good data governance and the inability to quantify possible risks associated with the use of their AI models,” stated Randolph Kahn Esq., President of Kahn Consulting Inc. “Consortiums such as AISIC can produce detailed guidelines and best practices, and when coupled with LatticeFlow AI’s technology, this can lead to a significant reduction of the time and cost required to complete thorough risk assessments and unlock the value of AI systems.”
The U.S. AI Safety Institute Consortium
AISIC was established by the U.S. Department of Commerce’s National Institute of Standards and Technology (NIST) to contribute to the priority actions outlined in U.S. President Biden’s Executive Order on the Safe, Secure, and Trustworthy Development and Use of AI. These include developing red-teaming guidelines, technical assessment standards, and risk management practices, among other key elements to the development of trustworthy AI and its responsible use.
LatticeFlow AI's Contributions to Making AI Safe and Trustworthy
LatticeFlow AI’s association with AISIC follows a series of contributions made by the LatticeFlow AI team towards the goals outlined by AISIC and President Biden’s Executive Order. Since 2020, LatticeFlow AI has been an invited technical contributor to key AI Safety initiatives at the International Organization for Standardization, where it has actively contributed to the working group focusing on the development and standards for Trustworthy AI. Earlier this year, LatticeFlow AI hosted renowned AI leaders at the World Economic Forum’s AI House, gathering key figures in AI, including Gary Marcus (NYU), Apostol Vassilev (NIST), Kai Zenner (European Parliament), Matthias Bossardt (KPMG), Thomas Stauner (BMW), among other industry experts, to delve into the latest AI developments and discuss responsible AI adoption.
From Standards to Practice: First AI Assessment for a Leading Swiss Bank
Moving beyond the development of AI guidelines and standards, this year, LatticeFlow AI announced the first industry-pioneering technical AI Assessment for Migros Bank, a leading Swiss Bank, demonstrating how these AI standards are used in practice to mitigate risk and ensure regulatory compliance for business-critical AI solutions. The results of this assessment, alongside a concrete blueprint to implement AI governance and technical AI assessments at enterprises and governments, were presented at a dedicated event hosted at the ETH AI Center.
LatticeFlow AI’s Commitment to the U.S. and NIST’s AI Safety Institute Consortium
With its contributions to AISIC, LatticeFlow AI will continue its commitment to helping U.S. government agencies such as the U.S. Army ensure the safety and trustworthiness of mission-critical AI systems. Last year, White House officials announced LatticeFlow AI as the first-place winner in the “red teaming” AI Privacy Prize Challenge category. Subsequently, the company announced a strategic expansion towards the US and a three-year strategic engagement with the U.S. Army to build next-generation resilient AI solutions for mission-critical defense use cases.
"Joining AISIC will allow us to accelerate and broaden our impact by aligning our efforts towards ensuring AI trust and safety with global AI leaders, enterprises, and governments," said Petar Tsankov, Co-founder and CEO of LatticeFlow AI.
Interested in learning more?
- Watch the replay of our event on AI Governance & Audits: Navigating AI Risks and Compliance.
- Visit our web page to learn how to manage your AI model risk with comprehensive technical AI assessments.
- If you are interested in conducting an AI assessment, book a meeting with a LatticeFlow AI expert.
About LatticeFlow AI
LatticeFlow AI offers a cutting edge AI platform that empowers enterprise teams to build performant, safe, and trustworthy AI at scale. Our platform is designed to unlock the full value of AI by systematically addressing critical model and data issues through automated processes and intelligent workflows across your entire AI lifecycle.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240423153331/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
